MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317872 | Name: Finasteride
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Finasteride is a 5α-reductase inhibitor that prevents the conversion of testosterone to dihydrotestosterone (DHT). It selectively inhibits type II 5α-reductase with an IC₅₀ of ~0.06 nM. This reduction in DHT levels leads to decreased androgenic stimulation in tissues such as the prostate and hair follicles, making it effective for treating benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA). Finasteride has a high binding affinity for 5α-reductase and results in a ~70% reduction in serum DHT at a 5 mg/day dose.

Chemical Structure

Finasteride
Finasteride
CAS#98319-26-7

Theoretical Analysis

MedKoo Cat#: 317872

Name: Finasteride

CAS#: 98319-26-7

Chemical Formula: C23H36N2O2

Exact Mass: 372.2777

Molecular Weight: 372.54

Elemental Analysis: C, 74.15; H, 9.74; N, 7.52; O, 8.59

Price and Availability

Size Price Availability Quantity
100mg USD 90.00 Ready to ship
200mg USD 150.00 Ready to ship
500mg USD 300.00 Ready to ship
1g USD 500.00 Ready to ship
2g USD 850.00 Ready to ship
5g USD 1,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Finasteride, Proscar, Eucoprost, Propecia, MK 906
IUPAC/Chemical Name
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
InChi Key
DBEPLOCGEIEOCV-WSBQPABSSA-N
InChi Code
InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
SMILES Code
C[C@]12CC[C@H]3[C@@H](CC[C@@H]4[C@]3(C)C=CC(N4)=O)[C@@H]1CC[C@@H]2C(NC(C)(C)C)=O
Appearance
Solid powder
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#C22B12B15
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Finasteride (MK-906) is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase with Ki of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).
In vitro activity:
5α-Reductase Inhibition (Type II Isoform, Human Prostate Microsomes) IC₅₀: ~0.06 nM [(Rasmusson et al., 1986)] 5α-Reductase Inhibition (Type I Isoform, Human Scalp and Liver Microsomes) IC₅₀: ~360 nM [(Steers et al., 1990)] Enzyme Binding and Kinetics Finasteride acts as a mechanism-based irreversible inhibitor, forming a stable complex with the enzyme. Exhibits slow dissociation kinetics, contributing to prolonged DHT suppression. Cell-Based Assays In LNCaP prostate cancer cells, finasteride reduces intracellular DHT levels in a dose-dependent manner. In dermal papilla cell cultures, finasteride prevents DHT-induced suppression of hair growth factors.
In vivo activity:
1. DHT Suppression in Humans Dose: 1 mg/day (for androgenetic alopecia) → ~65% reduction in serum DHT [(Kaufman et al., 1998)] Dose: 5 mg/day (for BPH) → ~70% reduction in serum DHT [(Gormley et al., 1992)] Intraprostatic DHT levels: Reduced by ~85% after chronic dosing [(Rittmaster et al., 1994)] 2. Prostate Size Reduction (BPH Patients) 5 mg/day for 6 months → ~20% reduction in prostate volume [(Gormley et al., 1992)] Long-term use (4 years) → ~50% lower risk of acute urinary retention and need for surgery [(McConnell et al., 1998; PLESS trial)] 3. Hair Growth in Androgenetic Alopecia 1 mg/day for 12 months → Increased hair count in ~66% of men [(Kaufman et al., 1998)] Sustained effects: Continued hair regrowth up to 5 years in clinical studies. 4. Animal Studies (Rodent and Canine Models) Male rats: Reduced prostate weight by ~50% at 1 mg/kg/day. Male dogs (which have 5α-reductase Type II like humans): Significant prostate shrinkage at 0.1–1 mg/kg/day. 5. Fertility and Hormonal Effects Men: No significant change in testosterone or LH levels despite DHT suppression. Rats: High doses led to reduced seminal vesicle and prostate weight but reversible upon discontinuation.
Solvent mg/mL mM
Solubility
DMSO 150.0 402.64
Ethanol 75.0 201.32
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 372.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Yun DK, Lee J, Keum YS. Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence. Biomol Ther (Seoul). 2013 Jan;21(1):49-53. doi: 10.4062/biomolther.2012.080. PMID: 24009858; PMCID: PMC3762299.
In vivo protocol:
1. Sirinarumitr K, Johnston SD, Kustritz MV, Johnston GR, Sarkar DK, Memon MA. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. J Am Vet Med Assoc. 2001 Apr 15;218(8):1275-80. doi: 10.2460/javma.2001.218.1275. PMID: 11330612.
1: Elkelany OO, Owen RC, Kim ED. Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus. Ther Clin Risk Manag. 2015 Mar 30;11:507-13. doi: 10.2147/TCRM.S80353. eCollection 2015. Review. PubMed PMID: 25848297; PubMed Central PMCID: PMC4386768. 2: Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014 Apr;25(2):156-61. doi: 10.3109/09546634.2013.813011. Epub 2013 Jul 5. Review. PubMed PMID: 23768246. 3: Boychenko O, Bernstein RM, Schweiger ES. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature. Cutis. 2012 Aug;90(2):73-6. Review. PubMed PMID: 22988650. 4: Berthold D, Lhermitte B, Uffer M, Doerfler A. Finasteride-related Leydig cell tumour: report of a case and literature review. Andrologia. 2012 May;44 Suppl 1:836-7. doi: 10.1111/j.1439-0272.2011.01214.x. Epub 2011 Sep 26. Review. PubMed PMID: 21950360. 5: Krome S. [How effective is finasteride?]. Dtsch Med Wochenschr. 2011 Feb;136(8):354. doi: 10.1055/s-0031-1275154. Epub 2011 Feb 23. Review. German. PubMed PMID: 21348003. 6: Hulin-Curtis SL, Petit D, Figg WD, Hsing AW, Reichardt JK. Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncol. 2010 Dec;6(12):1897-913. doi: 10.2217/fon.10.149. Review. PubMed PMID: 21142863. 7: Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010 Oct;146(10):1141-50. doi: 10.1001/archdermatol.2010.256. Review. PubMed PMID: 20956649. 8: Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006015. doi: 10.1002/14651858.CD006015.pub3. Review. PubMed PMID: 20927745. 9: Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction? Dermatol Ther. 2010 Sep-Oct;23(5):544-6. doi: 10.1111/j.1529-8019.2010.01358.x. Review. PubMed PMID: 20868409. 10: Chaudhary UB, Turner JS. Finasteride. Expert Opin Drug Metab Toxicol. 2010 Jul;6(7):873-81. doi: 10.1517/17425255.2010.495944. Review. PubMed PMID: 20536414. 11: Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010 Jun;44(6):1090-7. doi: 10.1345/aph.1M591. Epub 2010 May 4. Review. PubMed PMID: 20442354. 12: Lebdai S, Bigot P, Azzouzi AR. High-grade prostate cancer and finasteride. BJU Int. 2010 Feb;105(4):456-9. doi: 10.1111/j.1464-410X.2009.09089.x. Epub 2009 Nov 20. Review. PubMed PMID: 19930174. 13: Li J, Kim J. Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prev Res (Phila). 2009 Jun;2(6):518-24. doi: 10.1158/1940-6207.CAPR-08-0241. Epub 2009 Jun 2. Review. PubMed PMID: 19491289. 14: De Nunzio C, Miano R, Trucchi A, Finazzi Agrò E, Tubaro A. Finasteride for prostatic disease: an updated and comprehensive review. Expert Opin Drug Metab Toxicol. 2008 Dec;4(12):1561-8. doi: 10.1517/17425250802587058 . Review. PubMed PMID: 19040331. 15: Bhardwa J, Goldstraw M, Tzortzis S, Kirby R. Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2007 Jun;8(9):1337-44. Review. PubMed PMID: 17563267. 16: D'Amico AV, Barry MJ. Prostate cancer prevention and finasteride. J Urol. 2006 Nov;176(5):2010-2; discussion 2012-3. Review. PubMed PMID: 17070238. 17: Fleshner N, Kulkarni G. Should finasteride be used to prevent prostate cancer? Curr Treat Options Oncol. 2006 Sep;7(5):346-54. Review. PubMed PMID: 16904051. 18: Goetzl MA, Holzbeierlein JM. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nat Clin Pract Urol. 2006 Aug;3(8):422-9. Review. PubMed PMID: 16902518. 19: Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, Wiren KM. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev. 2006 Spring;12(1):53-76. Review. PubMed PMID: 16834758. 20: Canby-Hagino ED, Brand TC, Hernandez J, Thompson IM. Chemoprevention of prostate cancer with finasteride. Expert Opin Pharmacother. 2006 May;7(7):899-905. Review. PubMed PMID: 16634712.